These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34757064)

  • 41. Infectious complications of chimeric antigen receptor (CAR) T-cell therapies.
    Gea-Banacloche JC
    Semin Hematol; 2023 Jan; 60(1):52-58. PubMed ID: 37080711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
    Al-Juhaishi T; Ahmed S
    Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
    Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy.
    Little JS; Tandon M; Hong JS; Nadeem O; Sperling AS; Raje N; Munshi N; Frigault M; Barmettler S; Hammond SP
    Blood Adv; 2023 Sep; 7(18):5485-5495. PubMed ID: 37486599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.
    Wudhikarn K; Park JH
    Leuk Lymphoma; 2020 Oct; 61(10):2324-2334. PubMed ID: 32522059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
    J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress.
    Tchernonog E; Moignet A; Anota A; Bernard S; Bouguet G; Colin F; Rioufol C; Ysebaert L; Gyan E
    Haematologica; 2024 Aug; 109(8):2401-2419. PubMed ID: 38450528
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.
    Cohen AD
    Am Soc Clin Oncol Educ Book; 2018 May; 38():e6-e15. PubMed ID: 30231373
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature.
    Cheok KPL; Farrow A; Springell D; O'Reilly M; Morley S; Stone N; Roddie C
    Lancet Infect Dis; 2024 Apr; 24(4):e256-e265. PubMed ID: 38310904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Driving the CAR to the Bone Marrow Transplant Program.
    Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
    Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New targets for CAR T therapy in hematologic malignancies.
    Savani M; Oluwole O; Dholaria B
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bispecific CAR T-cells for B-cell Malignancies.
    Furqan F; Shah NN
    Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
    Sun Z; Xie C; Liu H; Yuan X
    Front Immunol; 2022; 13():778192. PubMed ID: 35154102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.
    Vanegas YM; Mohty R; Gadd ME; Luo Y; Aljurf M; Qin H; Kharfan-Dabaja MA
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):81-93. PubMed ID: 36537906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.